{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:53:28Z","timestamp":1773154408891,"version":"3.50.1"},"reference-count":51,"publisher":"Wiley","issue":"s6","license":[{"start":{"date-parts":[[2008,9,29]],"date-time":"2008-09-29T00:00:00Z","timestamp":1222646400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2008,11]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> We recommend prophylaxis in haemophilic children with an inhibitor as a way of preventing the musculoskeletal impairment that is likely to affect them. This approach has been used for children without inhibitors with excellent results. If prophylaxis is not feasible, we suggest that intensive on\u2010demand treatment should be given. Two agents, recombinant activated FVII (rFVIIa) and activated prothrombin complex concentrates (aPCC), are currently used to control haemostasis either for prophylaxis or intensive on\u2010demand treatment. As it is recombinant, rFVIIa would seem more appropriate to be employed in children. aPCC could be used in adults, or in the event of an unsatisfactory response to rFVIIa. We recommend prophylaxis or, at least, intensive on\u2010demand treatment in haemophilia children with inhibitors. Both rFVIIa and aPCC are being used for this purpose. It would seem that rFVIIa might be more appropriate for children as it is a recombinant product. Nevertheless, after skeletal maturity (in adults), both agents could be used indistinctively (taking into consideration that FEIBA is a plasma\u2010derived product). We still need more well\u2010designed comparative studies in order to be able to assert that our consensus\u2010based conclusion is evidence based. In orthopaedic surgery, both aPCC and rFVIIa have been reported to be effective in controlling perioperative haemostasis, although in practice most centres have so far used rFVIIa for their orthopaedic procedures. We recommend rehabilitation programmes for all patients with inhibitors in order to mitigate the disabling and handicapping impact of their condition and thereby enable them to achieve social integration. Programmes for haemophilic children without inhibitors can be applied to children with inhibitors but should be individually tailored.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2008.01892.x","type":"journal-article","created":{"date-parts":[[2008,9,29]],"date-time":"2008-09-29T07:54:30Z","timestamp":1222674870000},"page":"68-81","source":"Crossref","is-referenced-by-count":15,"title":["Prevention of haemophilic arthropathy during childhood. May common orthopaedic management be extrapolated from patients without inhibitors to patients with inhibitors?"],"prefix":"10.1111","volume":"14","author":[{"given":"E. C.","family":"RODRIGUEZ\u2010MERCHAN","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"HEDNER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"HEIJNEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"JIMENEZ\u2010YUSTE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. A.","family":"LEE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"MORFINI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"QUEROL","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"ROOSENDAAL","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"SANTAGOSTINO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. P.","family":"SOLIMENO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,9,29]]},"reference":[{"key":"e_1_2_8_2_2","unstructured":"DiMicheleD.The use of recombinant factor VIIa (NovoSeven) for central catheter insertion: an international experience. Abstract presented at the XVIth ISTH Congress Florence June 6\u201312 1997."},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00940.x"},{"key":"e_1_2_8_4_2","first-page":"26","article-title":"Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors","volume":"4","author":"Ingerslev J","year":"2000","journal-title":"Sem Thromb Hemost"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04173.x"},{"key":"e_1_2_8_6_2","unstructured":"NegrierC FleuryR HootsKWet\u00a0al.The use of FEIBA during surgeries in haemophilia patients with inhibitors to factor VIII and IX. Abstract no. P\u2010T\u2010172 XXIst ISTH Congress Geneva July 6\u201312 2007."},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0007-1048.2001.03324.x"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1999.00319.x"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615357"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199905)42:5<1025::AID-ANR23>3.0.CO;2-3"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1666930"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1999.00191.x"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00708.x"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1998.00396.x"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.00129.x"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1992.tb00546.x"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1976.tb16525.x"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02580.x"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01599.x"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01953.x"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067659"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00817.x"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01518.x"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01601.x"},{"key":"e_1_2_8_25_2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1055\/s-0038-1650216","article-title":"Safety profile of porcine FVIII and its use as hospital and home therapy for patients with haemophilia A and inhibitors: the results of an international survey","volume":"75","author":"Hay CR","year":"1996","journal-title":"Thromb Haemost"},{"key":"e_1_2_8_26_2","first-page":"97","article-title":"Preclinical and clinical experiences with a recombinant porcine FVIII product","volume":"644","author":"Abshire T","year":"2006","journal-title":"Haemophilia"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198008213030803"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198109243051301"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615388"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH05-07-0510"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-017988"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01403.x"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2001.00553.x"},{"key":"e_1_2_8_34_2","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1055\/s-0037-1616550","article-title":"Effective prophylaxis with daily recombinant factor VIIa (rFVIIa\u2010NovoSeven) in a child with high titre inhibitors and a target joint","volume":"86","author":"Saxon BR","year":"2001","journal-title":"Thromb Haemost"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01455.x"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02663.x"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.12.10.1111"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00771.x"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH07-03-0198"},{"key":"e_1_2_8_40_2","volume-title":"Go for it. Guidance on Physical Activity and Sports for People with Haemophilia and Related Disorders","author":"Jones T","year":"1998"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01447.x"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003086-199710000-00008"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00803.x"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01566.x"},{"key":"e_1_2_8_45_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00703.x"},{"key":"e_1_2_8_46_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.440514.x"},{"key":"e_1_2_8_47_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1999.00287.x"},{"issue":"2","key":"e_1_2_8_48_2","article-title":"Primary knee arthroplasty using recombinant factor VIIa (rFVIIa) as first\u2010line therapy in haemophilia patients with high responding inhibitors","volume":"5","author":"Laurian YD","year":"2007","journal-title":"J Thromb Haemost"},{"key":"e_1_2_8_49_2","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood.V76.2.354.354","article-title":"Properties of factor VIIa\/tissue factor complexes in an umbilical vein model","volume":"76","author":"Almus FE","year":"1990","journal-title":"Blood"},{"key":"e_1_2_8_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02576.x"},{"key":"e_1_2_8_51_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.1998.274.3.H769"},{"key":"e_1_2_8_52_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613832"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2008.01892.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2008.01892.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T13:34:08Z","timestamp":1694612048000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2008.01892.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9,29]]},"references-count":51,"journal-issue":{"issue":"s6","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["10.1111\/j.1365-2516.2008.01892.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2008.01892.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9,29]]}}}